Should You Buy Novo Nordisk Right Now?
Key Points
Novo Nordisk is drawing divided views from Wall Street analysts.
Some may be disappointed by the loss of market share to Eli Lilly.
Three events could turn sentiment positive in the coming months.
- 10 stocks we like better than Novo Nordisk ›
Wall Street analysts can't agree on Novo Nordisk (NYSE: NVO), with Morgan Stanley recently cutting its rating to underweight on the back of disappointing growth in key prescriptions in the U.S., and HSBC Holdings recently raising its rating to a buy on the strength of the potential of its pipeline. Who's right?
Novo Nordisk is a speculative buy.
The HSBC approach, in this case, may be sensible, at least on a risk-reward basis. The nearly 50% drop in Novo Nordisk shares is likely a reflection of the market's disappointment in Wegovy's (semaglutide) share loss in the weight loss market to Eli Lilly's Zepbound (tirzepatide).
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
That said, the company has a few upcoming events that could return the stock to favor. First, it's leading the race to get an oral weight loss pill (oral Wegovy) approved and expects a decision from the FDA this year. Moreover, there's data to suggest superiority over Eli Lilly's candidate, orforglipron.
Second, Novo Nordisk is trialing its next-generation weight loss drug, CagriSema, against Eli Lilly's tirzepatide in a phase 3 trial (REDEFINE 4), set for completion in mid-January.
Third, Novo Nordisk is set to release results from a phase 3 trial of semaglutide in Alzheimer's patients, scheduled for late 2025 or early 2026 -- the aim is to slow cognitive decline.
Image source: Getty Images.
A stock to buy
While there are definitely no guarantees, not least as CagriSema has disappointed with efficacy data previously, and according to Reuters, a Novo Nordisk executive has described the Alzheimer's trial as a "lottery," all three events offer upside potential. That potential shouldn't be easily discounted, particularly if its oral Wegovy gets approved for marketing by the FDA in 2025. As such, the stock could be of interest to more speculative investors.
Should you invest $1,000 in Novo Nordisk right now?
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $657,979!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,122,746!*
Now, it’s worth noting Stock Advisor’s total average return is 1,060% — a market-crushing outperformance compared to 187% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of October 7, 2025
HSBC Holdings is an advertising partner of Motley Fool Money. Lee Samaha has no position in any of the stocks mentioned. The Motley Fool recommends HSBC Holdings and Novo Nordisk. The Motley Fool has a disclosure policy.
Recommended Articles
